Moreover, the basal-like and HER2 subtypes of breast cancer are more sensitive to preoperative chemotherapy [5,6] and are more likely to undergo a pathologic complete response [7] but have a worse prognosis than luminal and normal-like cancers[8,9]. This evidence concerns the gene ERBB2 and breast carcinoma.